# Vedolizumab

## ENTYVIO inj 300mg (infusion)

##### 臨採

| TAH Drug Code      | [IENT](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IENT)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Crohn disease or ulcerative colitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | Crohn disease: IV: 300 mg at 0, 2, and 6 weeks and then every 8 weeks thereafter. Discontinue therapy in patients who show no evidence of therapeutic benefit by week 14. SUBQ: Maintenance: 108 mg once every 2 weeks beginning after at least 2 IV infusions; administer in place of next scheduled IV dose and then every 2 weeks thereafter. Missed dose: Administer next dose as soon as possible and then every 2 weeks thereafter. In the case of incomplete dose administration (eg, uncertain if full dose administered), notify health care provider. Ulcerative colitis: IV: 300 mg at 0, 2, and 6 weeks and then every 8 weeks thereafter. Discontinue therapy in patients who show no evidence of therapeutic benefit by week 14. SUBQ: Maintenance: 108 mg once every 2 weeks beginning after at least 2 IV infusions; administer in place of next scheduled IV dose and then every 2 weeks thereafter. Missed dose: Administer next dose as soon as possible and then every 2 weeks thereafter. In the case of incomplete dose administration (eg, uncertain if full dose administered), notify health care provider. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Hypersensitivity reaction, severe or serious, to vedolizumab or any of its excipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Adverse Effects    | Common: Nausea (9%), Arthralgia (12%), Headache (12%), Nasopharyngitis (13%), Upper respiratory infection (7%), Fatigue (6%), Fever (9%) Serious: Aminotransferase abnormal, Increased (Up to 2%), Hepatitis, Serum bilirubin above reference range, Anaphylaxis (0.07%), Hypersensitivity reaction, Progressive multifocal leukoencephalopathy, Tuberculosis, Cancer (0.4%), Infectious disease, Infusion reaction (4%), Sepsis (0.03%) [仿單] 上市後經驗: 呼吸系統、胸腔和縱膈疾病：間質性肺病、肺炎。                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| More Info          | [UpToDate](https://www.uptodate.com/contents/vedolizumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

## Entyvio inj 108mg/0.68mL 皮下注射

##### 臨採

| TAH Drug Code      | [IENTH](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IENTH)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of moderate to severe active ulcerative colitis and moderate to severe active Crohn's disease in adults. In patients who have responded inadequately, lost response, or are intolerant to treatment with tumor necrosis factor (TNF) blockers or immunomodulatory therapy; or in those who have shown inadequate response, intolerance, or demonstrated dependence on corticosteroid therapy.                                                                                                                                                                                                                                                                                                                                                                                                        |
| Dosing             | Crohn disease: SUBQ: Maintenance: 108 mg once every 2 weeks beginning after at least 2 IV infusions; administer in place of next scheduled IV dose and then every 2 weeks thereafter. Missed dose: Administer next dose as soon as possible and then every 2 weeks thereafter. In the case of incomplete dose administration (eg, uncertain if full dose administered), notify health care provider. Ulcerative colitis: SUBQ: Maintenance: 108 mg once every 2 weeks beginning after at least 2 IV infusions; administer in place of next scheduled IV dose and then every 2 weeks thereafter. Missed dose: Administer next dose as soon as possible and then every 2 weeks thereafter. In the case of incomplete dose administration (eg, uncertain if full dose administered), notify health care provider. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | Known severe or hypersensitive reaction to Entyvio or its excipients, such as difficulty breathing, bronchospasm, urticaria, flushing, rash, and increased heart rate.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | Common: Nausea (9%), Arthralgia (12%), Headache (12%), Nasopharyngitis (13%), Upper respiratory infection (7%), Fatigue (6%), Fever (9%) Serious: Aminotransferase abnormal, Increased (Up to 2%), Hepatitis, Serum bilirubin above reference range, Anaphylaxis (0.07%), Hypersensitivity reaction, Progressive multifocal leukoencephalopathy, Tuberculosis, Cancer (0.4%), Infectious disease, Infusion reaction (4%), Sepsis (0.03%) [仿單] 上市後經驗: 呼吸系統、胸腔和縱膈疾病：間質性肺病、肺炎。                                                                                                                                                                                                                                                                                                       |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| More Info          | [UpToDate](https://www.uptodate.com/contents/vedolizumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

